Gut microbiome-based interventions to prevent ICU-acquired infections: A systematic review and meta-analysis
In brief
Gut microbiome strategies showed no mortality benefit but linked to fewer ICU infections
Across 38 trials, neither selective digestive decontamination nor biotic supplements significantly reduced deaths. Both showed associations with fewer infections, especially pneumonia, but the review did not directly compare the approaches, and results varied across studies. Whether either strategy reliably prevents ICU infections remains uncertain.
- Journal
- Gut microbes (Q1)
- Published
- 19 November 2026
- Study design
- Systematic review / meta-analysis of RCTs
- Evidence level
- Level 1, High (CEBM 1a)
- Authors
- Elizabeth C Townsend, Samuel A Fisch, Natalie H Yip, Daniel E Freedberg
- PMID
- 43059105
- DOI
- 10.1080/19490976.2026.2765035
Why clinicians should know about it
- Picked for Critical Care and Intensive Care Medicine (paper of the day, 22 November 2026): Systematic review compares ICU infection-prevention interventions and outcomes
Abstract
Gut microbiome colonization with potential pathogens is common and often precedes clinical infection in the intensive care unit (ICU). Two key gut microbiome-based interventions seek to prevent infections yet use opposite approaches: selective digestive decontamination (SDD) utilizes antibiotics to eliminate potential pathogens, whereas biotic supplementation (prebiotics, probiotics, or synbiotics) aims to enrich beneficial microbes. In the absence of randomized controlled trials (RCTs) directly comparing these two interventions, this systematic review and meta-analysis sought to compare the effect sizes of SDD versus biotic interventions for mortality and infection-related outcomes. We searched PubMed for RCTs published between 2000 and 2025. Eligible studies recruited adult ICU patients, assessed SDD or biotics against a comparator (standard care or placebo), and reported on mortality and/or acquired infection-related outcomes. Pooled relative risks (RR) were calculated using random-effects models. Nine SDD trials involving 19,907 subjects and 29 biotic supplementation trials involving 5,483 subjects were included. When compared versus standard care or placebo, neither intervention significantly reduced overall mortality (SDD: RR = 0.96 [95%CI: 0.88-1.05]; biotics: RR = 0.93 [95%CI: 0.87-1.00]).SDD was associated with modestly lower observed risk for ICU acquired all-cause infections compared to biotics (SDD: RR = 0.76 [95%CI: 0.60-0.98]; biotics: RR = 0.82 [95%CI: 0.64-1.05], no statistically significant difference) and specifically lower risk for pneumonia (SDD: RR = 0.50 [95%CI: 0.26-0.96]; prebiotics and synbiotics: RR = 0.70 [95%CI: 0.54-0.90]). In conclusion, neither SDD nor biotics was significantly protective for mortality, but both types of interventions showed similarly promising protective associations with infections, especially pneumonia. The studies selected were heterogeneous, especially those testing biotic interventions.
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.